Business Context and Reporting Period
This Form 8-K Current Report was filed by Marchex, Inc. on January 25, 2023. The filing discloses the entry into a material definitive agreement regarding executive compensation and the appointment of certain officers.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity-based compensation arrangements.
Material Changes and Executive Compensation
On January 25, 2023, the Compensation Committee approved stock option grants and restricted stock grants under the 2021 Stock Incentive Plan for the following executive officers:
- Russell C. Horowitz: 51,000 stock options and 51,000 restricted shares.
- Ryan Polley: 50,000 stock options and 140,000 restricted shares.
- Michael Arends: 59,000 stock options and 59,000 restricted shares.
Terms of Awards:
- Valuation: Options and restricted stock are valued based on the closing price of Class B common stock on the Grant Date.
- Option Vesting: 25% vests on the first anniversary; the remainder vests quarterly over the next three years (6.25% per quarter).
- Restricted Stock Vesting: 25% vests annually on the first, second, third, and fourth anniversaries.
- Acceleration: Vesting accelerates upon certain events applicable to the executive officers.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future performance, or specific risk factors beyond the standard terms of the compensation agreements.
Investor Verification Checklist
- Verify the closing price of Marchex Class B common stock on January 25, 2023, to determine the exercise price of the options and the fair value of the restricted stock.
- Review the 2021 Stock Incentive Plan to understand the specific "certain events" that trigger accelerated vesting.
- Confirm the continued employment status of the named executives to ensure the grants remain valid.